TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast‐Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent
American Journal of Hematology · 2026
DOI: 10.1002/ajh.70248 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hematology, 2026. Verfasst von Naseema Gangat und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Myeloproliferative Disorders, Sulfonamides, Bridged Bicyclo Compounds, Heterocyclic, Mutation. Die Arbeit nennt 19 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Hematology, Mayo Clinic, Jacksonville, Florida, USA.
- Division of Hematology, Mayo Clinic, Scottsdale, Arizona, USA.
ORCID-Profile: Naseema Gangat, Abhishek Mangaonkar, Antoine N Saliba, James M Foran, Talha Badar, Ayalew Tefferi
Zitieren
APA
Gangat, N., Warraich, M., Kumar, S., Fatima, M., McCullough, K., Begna, K. H., Al-Kali, A., Patnaik, M. M., Hogan, W. J., Mangaonkar, A., Saliba, A. N., Torghabeh, M. H., Alkhateeb, H., Shah, M. V., Foran, J. M., Badar, T., Palmer, J. M., Yi, C. A., Pardanani, A., & Tefferi, A. (2026). TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast‐Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent. American Journal of Hematology. https://doi.org/10.1002/ajh.70248
Vancouver
Gangat N, Warraich M, Kumar S, Fatima M, McCullough K, Begna KH, et al. TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast‐Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent. American Journal of Hematology. 2026. doi:10.1002/ajh.70248
BibTeX
@article{Gangat2026,
author = {Gangat, Naseema and Warraich, Momna and Kumar, Sudhesh and Fatima, Mahnoor and McCullough, Kristen and Begna, Kebede H and Al-Kali, Aref and Patnaik, Mrinal M and Hogan, William J and Mangaonkar, Abhishek and Saliba, Antoine N and Torghabeh, Mehrdad Hefazi and Alkhateeb, Hassan and Shah, Mithun V and Foran, James M and Badar, Talha and Palmer, Jeanne M and Yi, Cecilia Arana and Pardanani, Animesh and Tefferi, Ayalew},
title = {TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast‐Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent},
journal = {American Journal of Hematology},
year = {2026},
doi = {10.1002/ajh.70248}
}
EUVIMED